Prevalence and Economic Impact

New Zealand Dementia Foundation > Research Radar > Prevalence and Economic Impact
Economic Impact of Dementia in New Zealand, 2016.


Alzheimers New Zealand (2016).

This report provides estimates of the prevalence and costs of dementia in New Zealand in 2016, updating earlier estimates published in 2008 and again in 2012. It also provides observations about changes that occur over time – changes since previous reports, the situation today and looking to the future.

CLICK HERE FOR ACCESS

Ageing and the Economics of Caring.


University of Auckland, Te Whare Wānanga o Tāmaki Makaurau, Retirement Policy and Research Centre. (2017).

The ageing of the population has economic and social implications for the New Zealand care industry, particularly for care workers. Includes discussion of costs and demands related to dementia.

CLICK HERE FOR ACCESS

International Price Comparisons of Alzheimer’s Drugs: A Way To Close the Affordability Gap.


Guk-Hee, S., Wimo, A., Gauthier, S., O’Connor, D., Ikeda, M., Homma, A., et al. (2009).
International Psychogeriatrics, 21(6), 1116-1126.

An international survey was conducted in 21 countries (Argentina, Australia, Brazil, the Dominican Republic, France, India, Japan, Macedonia, Mexico, New Zealand, Nigeria, the Philippines, Portugal, Serbia, South Korea, Switzerland, Taiwan, Thailand, Uganda, the U.K. and the U.S.A.) and the prices of Alzheimer’s drugs were compared.

CLICK HERE FOR ACCESS

Cohort Profile: Te Puawaitanga O Nga Tapuwae Kia Ora Tonu, Life and Living in Advanced Age: A Cohort Study in New Zealand (LiLACS NZ).


Kerse, N., Teh, R., Moyes, S. A., Broad, J., Rolleston, A., Gott, M., … & Adamson, A. (2015).
International Journal of Epidemiology, 44(6), 1823-1832.

LiLACS NZ is a longitudinal cohort study identifying predictors of successful advanced ageing. This paper describes the cohort. Maori were found to be more likely to have dementia. 

CLICK HERE FOR ACCESS

Trends in Survival Following Dementia Diagnosis: A Multinational Cohort Study.


Lo, H., Koponen, M., Roethlein, C., et al. (2023).
Research Square.

This multinational study on mortality risk after a dementia diagnosis has revealed that people with dementia in several countries are living longer. However, this trend is not observed in Aotearoa, New Zealand.

CLICK HERE FOR ACCESS

Living With Dementia in Aotearoa (LiDiA): A Feasibility Study for a Dementia Prevalence Study in Māori and Non-Māori Living in New Zealand. Dementia, doi:10.1177/14713012231173012.


Martinez-Ruiz A, Yates S, Cheung G, et al. (2023).
Dementia, (23)4, 343-365.

The aim of this feasibility study was to lay the groundwork for the first full-scale NZ dementia prevalence study representative of Māori, European, Pacific, and Asian peoples living in NZ.

CLICK HERE FOR ACCESS

Estimating the Incidence of Dementia in New Zealand: A Cohort Study Applying Capture-Recapture Modelling to Routinely Collected Linked Health Datasets.


Ma’u, E., Cullum, S., Mukadam, N., Davis, D., Rivera-Rodriguez, C., & Cheung, G. (2024).
The Lancet Regional Health–Western Pacific, 52.

This study used three linked national health data sets—interRAI, Public hospital discharges, and Pharmacy. It is the first study to provide estimates of age 60+ dementia incidence in NZ and for the four main ethnic groups, and suggests over a third of incident dementia cases are undiagnosed.

CLICK HERE FOR ACCESS

Prevalence and Geographical Variation of Dementia in New Zealand From 2012 to 2015: Brief Report Utilising Routinely Collected Data Within the Integrated Data.


Walesby, K. E., Exeter, D. J., Gibb, S., Wood, P. C., Starr, J. M., & Russ, T. C. (2020).

A population‐based retrospective cohort study was conducted, analysing routinely collected data, including mentions of dementia codes in hospital discharge (2012-2015) or cause of death data (2012), and “anti‐dementia” drug prescriptions (2012-2015). Using these datasets, approximately 2% of those aged ≥60 years were coded as having dementia, lower than published estimates. Dementia was higher in North Island; in 80‐ to 89‐year‐olds; among the Māori population when age‐standardised.

CLICK HERE FOR ACCESS

Quality of Life in Dementia: Formal Care and Costs in New Zealand.


Gallrach, F., Hornblow, A., Croucher, M., & Kirk, R. (2012).
Deutsch Med Wochenschr, 137(A81). 

This study measures the quality of life of persons with dementia and their informal caregivers in New Zealand and examines which interventions from primary and secondary care are helpful for enhancing quality of life and what they cost. 

ENQUIRE WITH YOUR LIBRARY FOR ASSISTANCE

The Frequency of Executive Cognitive Impairment in Elderly Rehabilitation Inpatients.


Kahokehr, A., Siegert, R.J., & Weatherall, M. (2004).
Journal of Geriatric Psychiatry, 17(2), 68–72.

The aim of this study was to determine the frequency of executive cognitive dysfunction among older patients in two rehabilitation wards in Wellington, New Zealand.

ENQUIRE WITH YOUR LIBRARY FOR ASSISTANCE

Burden of Alzheimer’s Disease: Population-Based Estimates and Projections for New Zealand, 2006–2031.


Yeh, L., & Johnson, E. (2008).
The Australian and New Zealand Journal of Psychiatry, 42(9), 828–836.

This study estimated the prevalence of Alzheimer’s disease (AD, including ‘mixed’ dementia) in New Zealand in 2006, and projects this out to 2031.

ENQUIRE WITH YOUR LIBRARY FOR ASSISTANCE